Eli Lilly’s forthcoming oral GLP-1 receptor agonist (orforglipron) for weight loss and type 2 diabetes is expected to be a weight loss blockbuster when it launches early 2026.
When Lilly launched its injectable GLP-1, Mounjaro, it did not anticipate the huge demand, and this eventually led to a long-term shortage while Lilly ramped up supply to keep ahead of demand.
In this article, we look at the lessons learned from the Mounjaro shortage and how Eli Lilly is planning to prevent potential shortages by implementing measures that aim to ensure a robust and uninterrupted supply upon the drug’s anticipated launch in 2026.
Substantial Pre-Launch Inventory
Lilly has already amassed nearly $550 million in pre-launch inventory of orforglipron, a move that is both early and sizable compared to industry norms. This stockpiling strategy is designed to avoid the supply constraints experienced with previous GLP-1 therapies like Mounjaro and Zepbound. By building inventory ahead of regulatory approval, Lilly aims to meet anticipated demand without delays.
Lilly’s Oral-GLP-1 Drug Orforglipron will be manufactured in the US
Expansion of U.S.-Based Manufacturing
To bolster production capacity, Lilly is investing significantly in domestic manufacturing infrastructure. The company plans to construct four new facilities across the United States, including what is projected to be the largest active pharmaceutical ingredient (API) plant in the country. This expansion is intended to support not only orforglipron but also other incretin-based therapies, enhancing supply chain resilience and reducing reliance on international suppliers.
Leveraging Small-Molecule Advantages
Unlike peptide-based GLP-1 drugs that require complex manufacturing and cold-chain logistics, orforglipron is a small-molecule compound. This characteristic simplifies production processes and facilitates large-scale manufacturing, enabling Lilly to produce the drug more efficiently and distribute it widely without the logistical challenges associated with injectable therapies.
Small Molecule Manufacturing Plant – A lot simpler and easier to scale production than Injectable GLP-1s
Final Thoughts
Lilly has expressed confidence in its ability to launch orforglipron globally without supply constraints. The company’s CEO, David Ricks, emphasized that the manufacturing strategy is designed to support a full-scale launch, ensuring that supply meets the projected demand from the outset.
Through these comprehensive measures, early inventory accumulation, significant manufacturing investments, and the inherent production advantages of a small-molecule drug, Eli Lilly is positioning itself to effectively meet the anticipated demand for orforglipron and prevent the supply shortages that have affected similar therapies in the past.
Liraglutide
From £81.60
Mounjaro
From £139.99
Wegovy Injection
From £119.99
Saxenda
From £244.90
Foundayo
From £63.25
Wegovy Tablets
From £55.00
Mysimba
From £98.90
Orlistat
From £39.89
